Actively Recruiting
Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)
Led by China National Center for Cardiovascular Diseases · Updated on 2026-05-28
1574
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Atrial fibrillation (AF) is a common heart rhythm disorder affecting millions worldwide and increasing risks of stroke, blood clots, and heart failure, which can greatly reduce quality of life. Catheter ablation is a key treatment to restore normal rhythm and has shown better results than medication. This study evaluates a new technique called pulsed electric field ablation (PFA), which targets heart cells while sparing nearby tissues, aiming to improve treatment success and protect heart function in a large randomized trial. Participants will receive either pulsed field ablation using a specialized catheter or traditional radiofrequency ablation. For paroxysmal AF, PFA involves isolating pulmonary veins and ablating the left atrial wall, while persistent AF treatment adds mitral valve isthmus ablation. The radiofrequency group will receive pulmonary vein isolation and additional ablation based on their condition. Both groups may receive medication or electrical cardioversion if normal rhythm is not restored during the procedure. During the study, participants will be monitored for 12 months after ablation to track AF recurrence, changes in AF burden, heart pumping function, and quality of life using surveys. Safety will also be assessed, including overall survival. The study involves regular follow-up visits and evaluations to compare the outcomes and safety of the two ablation methods over one year.
CONDITIONS
Brief Title
Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with atrial fibrillation who will accept catheter ablation
- Age 18 years or older
- Able to understand and sign the informed consent form
You will not qualify if you...
- Contraindications for catheter ablation (e.g., atrial thrombosis, decompensated heart failure)
- Previous catheter ablation
- Myocardial infarction or cardiac surgery/intervention within 3 months
- Stroke or transient ischemic attack within 6 months
- Allergy to iodine contrast agents
- Participation in other clinical trials for drugs or devices
- Pregnant, breastfeeding, or planning pregnancy
- Active infection
- Secondary atrial fibrillation due to rheumatic heart disease or hypertrophic cardiomyopathy
- Unable or unwilling to cooperate to complete the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Procedure day with hospital stay as clinically indicated
Participants undergo catheter ablation using either pulsed field ablation or radiofrequency ablation to treat atrial fibrillation.
1 procedure visit (in-person)
Duration - 12 months
Participants are monitored for recurrence of atrial fibrillation and changes in heart function and quality of life for up to 12 months after ablation.
Regular follow-up visits up to 12 months
Trial Site Locations
Total: 1 location
1
National Cardiovascular Diseases Center, Fuwai Hospital
Beijing, Beijing Municipality, China, 100037
Actively Recruiting
Research Team
Y
Yan Yao
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here